Medication development and testing in children and adolescents: Current problems, future directions

Archives of General Psychiatry

Volumn 54, Issue 9, 1997, Pages 871-876

  Vitiello, Benedetto ^a   Jensen, Peter S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ADOLESCENT; CHILD; CHILD PSYCHIATRY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL HEALTH SERVICE; PSYCHOPHARMACOTHERAPY; REVIEW;

EID: 0030773121     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830210119016     Document Type: Review

References (45)

1. Jensen PS, Vitiello B, Leonard H, Laughren T. Child and adolescent psychopharmacology: expanding the research base. Psychopharmacol Bull. 1994;30:3-8.
2. Jensen PS, Ryan ND, Prien R. Psychopharmacology of child and adolescent major depression. J Child Adolesc Psychopharmacol. 1992;2: 31-45.
3. American Academy of Pediatrics Committee on Drugs. Unapproved uses of approved drugs:the physician, the package insert, and the Food and Drug Administration: subject review. Pediatrics. 1996;98:143-145.
4. Biederman J, Baldessarini RJ, Wright V, Knee D, Hazmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD, I: efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784.
5. Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol. 1996;5:301-304.
6. Institute of Medicine. Research on Children and Adolescents With Mental, Behavioral, and Developmental Disorders. Washington, DC: National Academy Press; 1989. Publication 10M-89-07.
7. Committee for the Study of Research on Child and Adolescents Mental Disorders. Report card on the National Plan for Research on Child and Adolescent Mental Disorders. Arch Gen Psychiatry. 1995; 52:715-723.
8. Cowdry RW, Jensen PJ. Grading the progress of child and adolescent mental health research: NIMH perspectives. Arch Gen Psychiatry. 1995;52:732-734.
9. Food and Drug Administration. Labeling and prescription drug advertising: content and format of labeling for human prescription drugs. Federal Register. June 26, 1979;44:37434-37467.
10. Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs: revision of pediatric use subsection in the labeling. Federal Register. December 13, 1994;59:64240-64250.
11. Harrington R, Fudge H, Rutter M, Pickles A, Hill J. Adult outcomes of childhood and adolescent depression, I: psychiatric status. Arch Gen Psychiatry. 1990;47:465-473.
12. Maziade M, Gingras N, Rodrigue C, Bouchard S, Cardinal A, Gauthier B, Tremblay G, Cote S, Fournier C, Boutin P, Hamel M, Roy MA, Martinez M, Merette C. Long-term stability of diagnosis and symptom dimensions in a systematic sample of patients with onset of schizophrenia in childhood and early adolescence, I: nosology, sex and age of onset. Br J Psychiatry. 1996;169:361-370.
13. Ryan ND, Puig-Antich J, Ambrosini P, Rabinovich H, Robinson O, Nelson B, Iyengar S, Twomey J. The clinical picture of major depression in children and adolescents. Arch Gen Psychiatry. 1987; 44:854-861.
14. Farwell RF, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson JB. Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med. 1990;322:364-369.
15. Vitiello B, Jensen PS: Developmental perspectives in pediatric psychopharmacology. Psychopharmacol Bull. 1995;31:75-81.
16. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci. 1992;648: 371-382.
17. Whitaker-Azmitia PM, Zhang X, Clarke C. Effects of gestational exposure to monoamine oxidase inhibitors in rats: preliminary behavioral and neurochemical studies. Neuropsychopharmacology. 1994;11:125-132.
18. Fava M. Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1996;35:1292-1303.
19. Wilson JY. Pediatric pharmacology: the path clears for a noble mission. J Clin Pharmacol. 1993;33: 210-212.
20. Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, Krisher, Murphy SB, Pratt CB, Toledano S, Wiley JM, Yu AL. Ifosfamide/ carboplatin/etoposide (ICE) for recurrent malignant solid tumor of childhood: a pediatric oncology group phase I/II study. J Pediatr Hematol Oncol. 1995;17:265-269.
21. Conners CK. Methodology of antidepressant drug trials for treating depression in adolescents. J Child Adolesc Psychiatry. 1992;2:11-22.
22. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker Inc; 1982.
23. Geller B, Cooper TB, Schluchter MD, Warham JE, Carr, LG. Child and adolescent nortriptyline single dose pharmacokinetics parameters: final report. J Clin Psychopharmacol. 1987;7:321-323.
24. Smith Rogers A. A research agenda for the study of therapeutic agents in adolescents. J Adolesc Health. 1994;15:672-678.
25. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, and stages of puberty. Arch Dis Child. 1976;51:170-182.
26. Office of the Federal Register. Code of Federal Regulations 45 (Public Welfare), Part 46: Protection of Human Subjects. Washington, DC: Office of the Federal Register, National Archives and Records Administration: October 1, 1994(45 CFR Subtitle A):116-135.
27. Arnold LE, Stoff DM, Cook E, Cohen DJ, Kruesi M, Wright C, Hattab J, Graham P, Zametkin A, Castellanos FX, McMahon W, Leckman JF. Ethical issues in biological psychiatric research with children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34:929-939.
28. Coffey BJ. Ethical issues in child and adolescent psychopharmacology. Child Adolesc Psychiatr Clin North Am. 1995;4:793-807.
29. American Academy of Pediatrics Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 1995;95:286-294.
30. Leikin S. Minors' assent, consent, or dissent to medical research. IRB Rev Hum Subj Res. 1993; 15:1-7.
31. Glantz LH. Conducting research with children: legal and ethical issues. J Am Acad Child Molesc Psychiatry. 1996;35:1283-1291
32. Hoagwood K, Jensen PS, Fisher CB, eds. Ethical Issues in Mental Health Research with Children and Adolescents. Mahwah NJ: Lawrence Erlbaum Inc Press; 1996.
33. Safer D, Krager JM. The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics. 1994;94: 462-464
34. Zito JM, Riddle MA. Psychiatric pharmacoepidemiology for children and adolescents. Child Adolesc Psychiatr Clin North Am. 1995;4:77-95.
35. DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist JH, Reichler R, Katz R, Landau P. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial. J Am Acad Child Adolesc Psychiatry. 1992;31:45-49.
36. Food and Drug Administration: FDA Bureau of Drugs Clinical Guidelines. Guidelines for the Clinical Evaluation of Psychoactive Drugs in Infants and Children. Washington, DC: Superintendent of Documents, US Government; 1979. FDA publication 79-3055.
37. Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs: proposed revision of pediatric use subsection in the labeling. Federal Register. October 16, 1992;57:47423-47428.
38. Laughren TP. Regulatory issues in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1996;35:1276-1282.
39. Richters J, Arnold LEA, Jensen PS, Abikoff H, Conners CK, Greenhill L, Hechtman L, Hinshaw S, Pelham W, Swanson J. NIMH Collaborative Multisite, Multimodal Treatment Study of Children with ADHD, I: background and rationale. J Am Acad Child Adolesc Psychiatry. 1995;34: 987-1000.
40. Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells K. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996;35: 1304-1313.
41. Jensen PS, Hoagwood, Fisher CB. Bridging scientific and ethical perspectives: toward synthesis. In: Hoagwood K, Jensen PS, Fisher CB, eds. Ethical Issues in Mental Health Research with Children and Adolescents. Mahwah, NJ: Lawrence Erlbaum Inc Press; 1996:287-297.
42. Kruesi MJP, Swedo SE, Coffey ML, Hamburger SD, Leonard H, Rapoport JL. Objective and subjective side effects of research lumber punctures in children and adolescents. Psychiatr Res. 1988; 25:59-63.
43. Frader C, MacGrath PJ, Kay J, Adams S, Luke B, A prospective survey of reaction to blood tests by children and adolescents. Pain. 1990;40:53-60.
44. Smith M. Taking blood from chidden causes no more than minimal harm. J Med Ethics. 1985;11: 127-131.
45. Coté CJ, Kauffman RE, Troendle GJ, Lambert GH. Is the 'therapeutic orphan' about to be adopted? Pediatrics. 1996;98:118-123.